Lunasin—a multifunctional anticancer peptide from soybean

Keith R. Davis, Jun-ichi Inaba


Lunasin is a bioactive peptide that was originally isolated from soybean and has since been shown to have a number of biological activities, including both cancer chemopreventive and therapeutic activities. Our recent focus has been on determining the range of cancer types that lunasin can affect and the mechanism of action against specific cancers. We recently found that lunasin has significant therapeutic activity against non-small cell lung cancer (NSCLC) both in vitro and in vivo. Mechanistic studies using lunasin-sensitive and lunasin-resistant NSCLC cell lines revealed the lunasin blocks cell proliferation by inhibiting cell cycle progression at the G1/S phase interface and that this inhibition was associated with reduced Akt signaling. In addition, we found that these effects were linked to the inhibition of integrin signaling through αv-containing integrins. Our results provide strong support for the hypothesis that direct effects on integrin signaling represent a major mode of action responsible for lunasin’s anticancer activity. 


Lunasin, Bioactive peptide, Cancer Therapeutic, Integrins, Cell cycle, Non-small cell lung cancer

Full Text:



Galvez AF, de Lumen BO. A soybean cDNA encoding a chromatin-binding peptide inhibits mitosis of mammalian cells. Nat Biotechnol. 1999;17(5):495-500.

Dia VP, Mejia EG. Lunasin promotes apoptosis in human colon cancer cells by mitochondrial pathway activation and induction of nuclear clusterin expression. Cancer Lett. 2010;295(1):44-53.

Hsieh CC, Hernandez-Ledesma B, de Lumen BO. Lunasin, a novel seed peptide, sensitizes human breast cancer

MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Bio Interact. 2010;186(2):127-34.

McConnell EJ, Devapatla B, Yaddanapudi K, et al. The soybean-derived peptide lunasin inhibits non-small cell lung cancer cell proliferation by suppressing phosphorylation of the retinoblastoma protein. Oncotarget. 2014; 6(7):4649-4662.

Galvez AF, Chen N, Macasieb J, et al. Chemopreventive property of a soybean peptide (lunasin) that binds to deacetylated histones and inhibits acetylation. Cancer Res. 2001;61(20):7473-8.

Esposito L, Conti D, Ailavajhala R, et al. Lung Cancer: Are we up to the Challenge? Curr Genomics. 2010;11(7):513-8.

Jeong HJ, Jeong JB, Kim DS, et al. Inhibition of core histone acetylation by the cancer preventive peptide lunasin. J Agric Food Chem. 2007;55(3):632-7.

Hernandez-Ledesma B, Hsieh CC, de Lumen BO. Relationship between lunasin's sequence and its inhibitory activity of histones H3 and H4 acetylation. Mol Nutr Food Res. 2011;55(7):989-98.

Galvez AF, Huang L, Magbanua MM, et al. Differential expression of thrombospondin (THBS1) in tumorigenic and nontumorigenic prostate epithelial cells in response to a chromatin-binding soy peptide. Nutr Cancer. 2011;63(4):623-36.

Inaba J, McConnell EJ, Davis KR. Lunasin sensitivity in non-small cell lung cancer cells is linked to suppression of integrin signaling and changes in histone acetylation. Int J Mol Sci. 2014;15(12):23705-24.

Howe A, Aplin AE, Alahari SK, et al. Integrin signaling and cell growth control. Curr Opin Cell Biol. 1998;10(2):220-31.

Dedhar S. Cell-substrate interactions and signaling through ILK. Curr Opin Cell Biol. 2000;12(2):250-6.

Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol. 2010;11(4):288-300.

Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285(5430):1028-32.

Hsu AR, Veeravagu A, Cai W, et al. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Rec Patents Anti-cancer Drug Discov. 2007;2(2):143-58.

Hughes PE, Diaz-Gonzalez F, Leong L, et al. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem. 1996;271(12):6571-4.

Vinogradova O, Velyvis A, Velyviene A, et al. A structural mechanism of integrin alpha(IIb)beta(3) "inside-out" activation as regulated by its cytoplasmic face. Cell. 2002;110(5):587-97.

Tadokoro S, Shattil SJ, Eto K, et al. Talin binding to integrin beta tails: a final common step in integrin activation. Science. 2003;302(5642):103-6.

Kloeker S, Major MB, Calderwood DA, et al. The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion. J Biol Chem. 2004;279(8):6824-33.

Shi X, Ma YQ, Tu Y, et al. The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility. J Biol Chem. 2007;282(28):20455-66.

Bouaouina M, Lad Y, Calderwood DA. The N-terminal domains of talin cooperate with the phosphotyrosine binding-like domain to activate beta1 and beta3 integrins. J Biol Chem. 2008;283(10):6118-25.

Bottcher RT, Lange A, Fassler R. How ILK and kindlins cooperate to orchestrate integrin signaling. Curr Opin Cell Biol. 2009;21(5):670-5.

Puklin-Faucher E, Sheetz MP. The mechanical integrin cycle. J Cell Sci. 2009;122(Pt 2):179-86.

Morse EM, Brahme NN, Calderwood DA. Integrin cytoplasmic tail interactions. Biochemistry. 2014;53(5):810-20.

Hohenester E. Signalling complexes at the cell-matrix interface. Curr Opin Struct Biol. 2014;29:10-6.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the '' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.


Number of visits since October, 2013